~~<i id='7359EEE896'><strike id='7359EEE896'><tt id='7359EEE896'><pre id='7359EEE896'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：hotspot 2025-09-30 11:59:05 Page View：64

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Georgia court denies Trump's request to quash DA's 2020 election probe
Next article： Psychedelics group wrestles with new pharma identity

explore

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Blood tests recalled over risk of missed heart attack diagnosis

AdobeQuidelOrthohasrecallednearly8,000potentiallyfaultybloodtestsmeanttohelpdoctorsquicklydeterminew

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Prime Medicine says its gene editing passes test in monkeys

DavidLiuproposedprimeeditingofgenesin2019.Thetechnologyhaspassedabigtest.CourtesyErikJacobs/BroadIns